Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990–2002

Feltbower, Richard; McNally, Richard J.Q.; Kinsey, Sally; Lewis, Ian; Picton, Susan; Proctor, Stephen J.; Richards, Michael; Shenton, Geoff; Skinner, Rod; Stark, Daniel P.; Vormoor, Josef; Windebank, Kevin; McKinney, Patricia A.

doi:10.1016/j.ejca.2008.09.020

Cited by 27 publications

(31 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, the age-specific OS rates observed in this region were similar to that observed in other regions of the United Kingdom. 4,24 The results clearly demonstrate that the incidence of cytogenetic and immunophenotypic subgroups varies markedly with the age. Although it is known that the incidence of specific chromosomal abnormalities differs between children and adults, the age-specific frequency of such lesions within adult ALL, especially among those older than 60 years of age, was hitherto unknown or poorly studied.…”

Section: Discussionmentioning

confidence: 50%

See 1 more Smart Citation

A population-based cytogenetic study of adults with acute lymphoblastic leukemia

Moorman

Chilton

Wilkinson

et al. 2010

Blood

Self Cite

215

157

View full text Add to dashboard Cite

Chromosomal abnormalities are increasingly used to risk stratify adults with acute lymphoblastic leukemia. Published data describing the age-specific incidence of chromosomal abnormalities and their prognostic relevance are largely derived from clinical trials. Trials frequently have age restrictions and low recruitment rates. Thus we investigated these factors in a population-based cohort of 349 patients diagnosed during the course of 19 years in the northern part of England. The incidence of most chromosomal abnormalities varied significantly with age.The incidence of t(9;22)(q34;q11) increased in each successive decade, up to 24% among 40-to 49-year-old subjects. Thereafter the incidence reached a plateau. t(4;11)(q21;q23) and t(1;19)(q23; p13) were a rare occurrence among patients older than 60 years of age. In contrast, the frequency of t(8;14)(q24;q32) and t(14;18)(q32;q21) increased with age. High hyperdiploidy occurred in 13% of patients younger than 20 years of age but in only 5% of older patients. The incidence of low hypodiploidy/near-triploidy and complex karyotype increased with age from 4% (15-29 years) to 16% (> 60 years). Overall survival varied significantly by age and cytogenetics. Older patients and those with t(9;22), t(4;11), low hypodiploidy/near-triploidy, or complex karyotype had a significantly inferior outcome. These population-based results demonstrate the cytogenetic heterogeneity of adult acute lymphoblastic leukemia. These data will inform the delivery of routine clinical services and the design of new age-focused clinical trials. (Blood. 2010;115:206-214)

show abstract

Section: Discussionmentioning

confidence: 50%

“…However, trial recruitment is much lower among adolescents and adults. 4 Moreover, adults older than 60 years of age are rarely eligible for clinical trials. 5,6 Population-based studies of adult ALL are rare.…”

Section: Introductionmentioning

confidence: 99%

A population-based cytogenetic study of adults with acute lymphoblastic leukemia

Moorman

Chilton

Wilkinson

et al. 2010

Blood

Self Cite

215

157

View full text Add to dashboard Cite

show abstract

“…4,123 In Northern England, 92% of 0-to 14-year-olds with leukemia were enrolled onto a clinical trial, compared with 60% of patients between the ages of 15 and 24 years. 124 Throughout England, overall accrual rates for all patients with new malignancies between 2005-2007 were 25% for 15-to 19-year-olds and 13% for 20-to 24-year-olds, 125 with another study estimating an enrollment rate of 8% among 35-to 39-year-olds. 126 A study at the Children's Hospital of Pittsburgh and the University of Pittsburgh Cancer Institute showed that 26% of AYA patients with new cancer diagnoses at the pediatric center were enrolled on a trial, 127 and 4% of those seen at the adult center were placed on trials.…”

Section: Access To Clinical Trialsmentioning

confidence: 99%

Malignant hematologic diseases in adolescents and young adults

Wood

Lee

2011

Blood

103

101

View full text Add to dashboard Cite

“…A range of ascertainment validation procedures were carried out to ensure optimal completeness (van Laar et al, 2010), including cross-checks with national clinical trials (Feltbower et al, 2009) and the regional Haematological Malignancy Research Network (www.hmrn.org/about/info).…”

Section: Methodsmentioning

confidence: 99%

Survival of childhood acute lymphoid leukaemia in Yorkshire by clinical trial era, 1990–2011

Laar

Kinsey²,

Feltbower

2015

Br J Haematol

Self Cite

View full text Add to dashboard Cite

SummaryGender-specific differences in survival by clinical trial era in Yorkshire were assessed for children with acute lymphoid leukaemia (ALL) enrolled onto UKALLXI, ALL97/ 99 or UKALL2003 (n = 630; 1990-2011). For males, there was a non-significant improvement in survival for ALL97/99 [hazard ratio (HR) = 0Á77; 95% confidence interval (CI) 0Á43-1Á42) and a significant improvement for UKALL2003 (HR = 0Á50; 95%CI 0Á25-0Á99) compared to UKALLXI. For females, survival was significantly improved for ALL97/99 (HR = 0Á33; 95%CI 0Á14-0Á78), and non-significantly improved for UKALL2003 (HR = 0Á51; 95%CI 0Á25-1Á08) compared to UKALLXI. Modest overall survival improvements masked clinically important gender-specific changes over time by trial era, requiring confirmation in larger population-based studies.

show abstract

Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990–2002

Cited by 27 publications

References 29 publications

A population-based cytogenetic study of adults with acute lymphoblastic leukemia

A population-based cytogenetic study of adults with acute lymphoblastic leukemia

Malignant hematologic diseases in adolescents and young adults

Survival of childhood acute lymphoid leukaemia in Yorkshire by clinical trial era, 1990–2011

Contact Info

Product

Resources

About